Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Pain
Interventions: Intravitreal injection site; Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Interventions: Faricimab Injection, sham treatment; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetic Retinopathy
Interventions: Color fundus photography, Mydriatic Agent; Procedure · Drug
Lead sponsor: Eyenuk, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Interventions: Remigromig, Aflibercept 2.0 mg; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more

Conditions: Diabetes Mellitus, Macular Edema
Interventions: Vitamin E; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy, Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years to 80 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Uveitis, Vasculitis, Ocular Inflammatory Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Interventions: No intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Macular Edema With Central Retinal Vein Occlusions
Interventions: Aflibercept (2.0 mg); Drug
Lead sponsor: Northern California Retina Vitreous Associates; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Pigment Epithelial Detachment
Interventions: iSONEP (sonepcizumab/LT1009); Drug
Lead sponsor: Lpath, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Winter Haven, Florida • West Mifflin, Pennsylvania • West Columbia, South Carolina + 2 more

Conditions: Diabetic Macular Edema
Interventions: LKA651, Lucentis; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more

Conditions: Wet Macular Degeneration
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 59
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more

Conditions: Retinal Vein Occlusion
Interventions: Dexamethasone intravitreal implant, Monthly Ranibizumab; Drug
Lead sponsor: Brian Burke, MPH; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions: nicotinic acid; Drug
Lead sponsor: Palo Alto Medical Foundation; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
Interventions: Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears; Drug
Lead sponsor: Retina Research Institute, LLC; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetic Retinopathy
Interventions: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®), Nepafenac ophthalmic suspension vehicle; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
Interventions: APX3330, Placebo; Drug
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 24
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab, Conventional Laser for ROP; Drug · Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 4 Weeks to 22 Weeks
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 15
States / cities: Pasadena, California • Denver, Colorado • Peoria, Illinois + 7 more

Conditions: Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Glaucoma
Interventions: Apraclonidine 1.0% ophthalmic solution; Drug
Lead sponsor: Retina Consultants of Delmarva; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Easton, Maryland

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions: ABBV-RGX-314, Ranibizumab (LUCENTIS®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 89
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more

Conditions: Diabetic Retinopathy
Interventions: BI 765128, Sham comparator; Drug · Other
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Bakersfield, California • Sacramento, California • Walnut Creek, California + 7 more

Conditions: Diabetic Retinopathy (DR), Macular Edema (ME)
Interventions: Animated Videos; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetic Macular Edema
Interventions: bevacizumab, PASCAL Endpoint Management (EpM) laser treatment; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate; Drug
Lead sponsor: Retina Vitreous Associates of Florida; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St. Petersburg, Florida

Search by objective public record fields.

Intravitreal Injection Site and Perceived Pain

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

Assessment of EyeArt Performance With Retinal Imaging Devices

A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO

Laser and Medical Treatment of Diabetic Macular Edema

The Relationship Between Advanced Glycation Endproducts and Diabetes

The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease

Imaging Parameters and DME Treatment Response

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

Macular Edema Incidence/Severity Reduction With Nevanac

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity

Iopidine to Decrease Intraocular Pressure Rise After Injections

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

Video Intervention to Improve Understanding of Diabetic Retinopathy at Zuckerberg San Francisco General Hospital and Trauma Center

Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections